Research programme: calcium-sensing receptor antagonists - NPS Pharmaceuticals/GlaxoSmithKline

Drug Profile

Research programme: calcium-sensing receptor antagonists - NPS Pharmaceuticals/GlaxoSmithKline

Alternative Names: Calcilytics - NPS Pharmaceuticals/GlaxoSmithKline; NPS 2143; NPS 89636; SB-262470; SKF 45675

Latest Information Update: 10 Aug 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NPS Pharmaceuticals
  • Class Naphthalenes; Pyrimidinones; Small molecules
  • Mechanism of Action Calcium-sensing receptor antagonists; Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 03 Aug 2011 Discontinued - Preclinical for Postmenopausal osteoporosis in USA (IV)
  • 03 Aug 2011 Discontinued - Preclinical for Postmenopausal osteoporosis in USA (PO)
  • 03 Aug 2011 Research programme: calcium-sensing receptor antagonists is no longer licensed to GlaxoSmithKline worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top